A Response to the Brill Analysis for Proper Data Exclusivity Periods for Innovator Biologics

Posted: 1 Apr 2009

See all articles by John A. Vernon

John A. Vernon

University of North Carolina (UNC) at Chapel Hill; National Bureau of Economic Research (NBER)

Joseph H. Golec

University of Connecticut - Department of Finance

Date Written: March 31, 2009

Abstract

In this note we critique the Brill analysis for proper data exclusivity periods for innovator biologics.

Keywords: Follow on Biologics, Data Exclusivity, Biotech Financial Risk

JEL Classification: I11, K00

Suggested Citation

Vernon, John A. and Golec, Joseph, A Response to the Brill Analysis for Proper Data Exclusivity Periods for Innovator Biologics (March 31, 2009). Available at SSRN: https://ssrn.com/abstract=1371020 or http://dx.doi.org/10.2139/ssrn.1371020

John A. Vernon (Contact Author)

University of North Carolina (UNC) at Chapel Hill ( email )

102 Ridge Road
Chapel Hill, NC NC 27514
United States

National Bureau of Economic Research (NBER)

1050 Massachusetts Avenue
Cambridge, MA 02138
United States

Joseph Golec

University of Connecticut - Department of Finance ( email )

School of Business
2100 Hillside Road
Storrs, CT 06269
United States

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
77
Abstract Views
597
Rank
563,377
PlumX Metrics